Sabril FDA Approval History
FDA Approved: Yes (First approved August 21, 2009)
Brand name: Sabril
Generic name: vigabatrin
Dosage form: Tablets and Oral Solution
Company: Lundbeck Inc.
Treatment for: Epilepsy, Seizures
Sabril (vigabatrin) is an oral irreversible GABA-transaminase inhibitor for the treatment of Infantile Spasms and refractory complex partial seizures.
Development timeline for Sabril
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
